Top Markets
Coin of the day
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR
株式のランク #18066
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
株価
$3.54
最終同期: 2026-09-02
時価総額
$213.59M
変化(1日)
3.06%
変化(1年)
-3.94%
US
取引 Voyager Therapeutics, Inc. (VYGR)

カテゴリー

Voyager Therapeutics, Inc.(VYGR)の株価履歴
終値の最高値: $3.48 (2026-09-01)

終値の最安値: $21.80 (2015-11-01)
Voyager Therapeutics, Inc. の株価履歴(2015 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -5.39%
2025 -31.67%
2024 -23.54%
2023 35.12%
2022 105.49%
2021 -64.56%
2020 -41.72%
2019 39.09%
2018 -32.12%
2017 8.56%
2016 -42.81%
2015 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.33 -8.75%
AU
$757.71 6.76%
CH